Roche Amends Boniva Suits Against Teva
The suits were first filed Aug. 12 in U.S. District Court for the District of New Jersey, asserting U.S. Patent Number 7,410,957, which was also issued Aug. 12, and other patents. The '957 patent expires on May 6, 2023.
The complaints also assert U.S. Patent Number 7,192,938, which expires May 6, 2023, and U.S....
To view the full article, register now.